Literature DB >> 16837971

Predicting benefit from anti-angiogenic agents in malignancy.

Adrian M Jubb1, Adam J Oates, Scott Holden, Hartmut Koeppen.   

Abstract

A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16837971     DOI： 10.1038/nrc1946

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  85 in total

1.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors.

Authors:  Wiem Lassoued; Danielle Murphy; Jeff Tsai; Ridha Oueslati; Gavin Thurston; William M F Lee
Journal:  Cancer Biol Ther       Date:  2010-12-15       Impact factor: 4.742

3.  RQN-18690A (18-deoxyherboxidiene) targets SF3b, a spliceosome component, and inhibits angiogenesis.

Authors:  Hideaki Kakeya; Daisuke Kaida; Hiromi Sekiya; Koji Nagai; Minoru Yoshida; Hiroyuki Osada
Journal:  J Antibiot (Tokyo)       Date:  2015-09-09       Impact factor: 2.649

4.  Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Authors:  Ernest S Han; Robert A Burger; Kathleen M Darcy; Michael W Sill; Leslie M Randall; Dana Chase; Basmina Parmakhtiar; Bradley J Monk; Benjamin E Greer; Patrick Connelly; Koen Degeest; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2010-09-25       Impact factor: 5.482

Review 5.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 6.  Methods and challenges in quantitative imaging biomarker development.

Authors:  Richard G Abramson; Kirsteen R Burton; John-Paul J Yu; Ernest M Scalzetti; Thomas E Yankeelov; Andrew B Rosenkrantz; Mishal Mendiratta-Lala; Brian J Bartholmai; Dhakshinamoorthy Ganeshan; Leon Lenchik; Rathan M Subramaniam
Journal:  Acad Radiol       Date:  2015-01       Impact factor: 3.173

7.  Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.

Authors:  Jie Ma; David J Waxman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Authors:  Veronica C Ardi; Philippe E Van den Steen; Ghislain Opdenakker; Bernhard Schweighofer; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

Review 9.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

Authors:  Dan G Duda; Rakesh K Jain; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

10.  PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.

Authors:  S W Huang; J C Lien; S C Kuo; T F Huang
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.